NASDAQ · PRLD
Prelude Therapeutics Incorporated
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PRLD: Nov 11, 2026
Prelude Therapeutics Incorporated Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.14. The reported EPS for the same quarter last year was $-0.26.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.14 | $-0.13 | $-0.16 | 2 |
| Dec 2026 | $-0.16 | $-0.14 | $-0.17 | 2 |
| Mar 2027 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Jun 2027 | $-0.16 | $-0.16 | $-0.16 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · MarketBeat · RTTNews- Zacks · Oct 27, 11:56 AM EDTCan Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?Can THC deliver a Q3 earnings beat? Ambulatory Care growth and higher revenues per adjusted admission offer support, but hospital volume declines and costs loom.
- MarketBeat · Oct 22, 11:02 PM EDTPrelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte OptionAnalysts are Upgrading These 3 Stocks…Here’s WhyPrelude Therapeutics (NASDAQ:PRLD) outlined progress across three priority programs at a Chardan Capital investor session, emphasizing its recently initiated JAK2 program, an IND-cleared KAT6A degrader for breast cancer and a mutant
- RTTNews · Oct 16, 10:55 AM EDTWeekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data(RTTNews) – This week's healthcare roundup brings a series of regulatory wins, corporate restructuring, billion-dollar deals and clinical milestones.
- Zacks · Oct 16, 8:35 AM EDTDown 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a TurnaroundPrelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- RTTNews · Oct 13, 8:33 AM EDTPrelude Therapeutics, Lilly Partner To Evaluate PRT13722 In Breast Cancer Trial(RTTNews) – Prelude Therapeutics Incorporated (PRLD) has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company (LLY) to evaluate PRT13722 in combination with Verzenio (abemaciclib) and Inluriyo (imlunestrant) in patients with HR+/HER2- breast
- RTTNews · Oct 13, 8:08 AM EDTPrelude, Lilly Partner On Breast Cancer Combination Trial; Stock Up(RTTNews) – Tuesday, Prelude Therapeutics Incorporated (PRLD) announced a clinical trial collaboration with Eli Lilly (LLY) to evaluate PRT13722 in combination with Verzenio (abemaciclib) and Inluriyo (imlunestrant) in patients with HR+/HER2- breast cancer.
- RTTNews · Sep 10, 9:24 AM EDTPrelude Therapeutics Receives FDA Clearance For PRT13722 IND In HR+/HER2-Breast Cancer(RTTNews) – Prelude Therapeutics Incorporated (PRLD), a precision oncology company, announced that the U.S. FDA has cleared its IND application for PRT13722.
- RTTNews · Aug 24, 6:34 AM EDTBiotech Stocks At 52-Week Highs – ELOX, PRLD, ARGX, BOLD, CORT(RTTNews) – The following biotech stocks reached a 52-week high on August 21, 2026, as new trials continued enrolment and companies released positive clinical research data.
- RTTNews · Aug 13, 2:44 AM EDTPrelude Narrows Loss In Q2 On Lower Costs; Expects Initiation Of PRT13722 Phase 1 In Q4 FY26(RTTNews) – Prelude Therapeutics Incorporated (PRLD), a clinical-stage precision-oncology company, reported second quarter results, showing a narrower loss primarily driven by increased revenue and reduced Research and Development (R&D) costs.
- Zacks · Jul 31, 9:55 AM EDTWall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?The consensus price target hints at a 58.4% upside potential for Prelude Therapeutics (PRLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- RTTNews · Jul 28, 10:44 PM EDTTop Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?(RTTNews) – Today's top biotech gainers include Trinity Biotech, which recently completed reverse split; OPKO Health, driven by its second-quarter financial results and continued pipeline progress; Kiniksa Pharma, after raising its revenue outlook on strong commercial momentum; a
- Zacks · Jul 17, 12:00 PM EDTPrelude Therapeutics (PRLD) Upgraded to Buy: Here's WhyPrelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Prelude Therapeutics Incorporated from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.